Literature DB >> 27453217

Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma.

Sarah P Psutka1, John C Cheville2, Brian A Costello3, Suzanne B Stewart-Merrill4, Christine M Lohse5, Bradley C Leibovich6, Stephen A Boorjian6, R Houston Thompson7.   

Abstract

OBJECTIVE: To evaluate the concordance of pathologic features in metastatic renal cell carcinoma (RCC) between the primary nephrectomy and metastasectomy specimens.
METHODS: Primary nephrectomy (n = 454) and matched metastasectomy specimens (n = 680) from patients treated between 1970 and 2009 for RCC were re-reviewed by 1 urologic pathologist in a blinded fashion. RCC histologic subtype, grade, coagulative necrosis, and the presence of sarcomatoid differentiation were compared between the primary and the metastatic tumor with kappa statistics.
RESULTS: Concordance with the primary tumor was observed for subtype in 647 (95%, kappa = 0.71) of the metastases, for grade in 411 (60%, kappa = 0.35), necrosis in 460 (68%, kappa = 0.32), and sarcomatoid differentiation in 643 (95%, kappa = 0.60). Upgrading was observed in 100%, 63%, and 13% of patients with grades 1, 2, and 3 primary tumors, respectively (no patient had a grade 1 metastatic lesion). Metastatic tumors treated with metastasectomy within 30 days of nephrectomy (n = 145) had similar rates of concordant subtype, necrosis, and sarcomatoid differentiation to those undergoing metastasectomy beyond 30 days from nephrectomy (P >.05 for all), but had higher rates of concordant grade (71% vs 58%, P = .003). Pre-metastasectomy exposure to systemic targeted or immunotherapy was not associated with a change in concordance of histopathologic features.
CONCLUSION: Among 454 surgically managed metastatic RCC patients, we observed a high degree of concordance for histologic subtype and sarcomatoid differentiation, and varying degrees of discordance for grade and coagulative tumor necrosis, between primary and metastatic tumors. Further investigation is warranted to understand the biologic and therapeutic implications of these observations. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27453217     DOI: 10.1016/j.urology.2016.06.061

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  [Is surgical treatment ever indicated in metastatic renal cell carcinoma and if so, based on which scientific rationale?]

Authors:  M Burger
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

2.  Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases.

Authors:  Julien Dagher; Solène-Florence Kammerer-Jacquet; Frédéric Dugay; Marion Beaumont; Alexandra Lespagnol; Laurence Cornevin; Grégory Verhoest; Karim Bensalah; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau
Journal:  Virchows Arch       Date:  2017-05-10       Impact factor: 4.064

3.  BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Authors:  Jeanette E Eckel-Passow; Daniel J Serie; John C Cheville; Thai H Ho; Payal Kapur; James Brugarolas; R Houston Thompson; Bradley C Leibovich; Eugene D Kwon; Richard W Joseph; Alexander S Parker
Journal:  BMC Urol       Date:  2017-03-21       Impact factor: 2.264

4.  Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

Authors:  Guillermo de Velasco; Stephanie A Wankowicz; Russell Madison; Siraj M Ali; Craig Norton; Audrey Duquette; Jeffrey S Ross; Dominick Bossé; Aly-Khan A Lalani; Vincent A Miller; Philip J Stephens; Lauren Young; A Ari Hakimi; Sabina Signoretti; Sumanta K Pal; Toni K Choueiri
Journal:  Br J Cancer       Date:  2018-04-20       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.